EMA Withdrawn: Zalmoxis (allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)) — MolMed SpA

View source ↗

Summary

The EMA withdrew Zalmoxis, a gene-modified allogeneic T cell product for hematopoietic stem cell transplantation and graft-versus-host disease indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematopoietic Stem Cell Transplantation-related Indications

Drugs mentioned

• Zalmoxis

Snippet

Status: Withdrawn. Therapeutic area: Hematopoietic Stem Cell Transplantation;Graft vs Host Disease. MAH: MolMed SpA. Decision date: 26/07/2018. Conditional approval